

# pFUSE-CHIg-hG4

Plasmid featuring the constant region of the human IgG4 heavy chain

Catalog # pfuse-hchg4

## For research use only

Version # 12I25-MM

## PRODUCT INFORMATION

### Content:

- 20 µg of pFUSE-CHIg-hG4 plasmid provided as lyophilized DNA
- 4 pouches of *E. coli* Fast-Media® Zeo (2 TB and 2 Agar)

### Storage and Stability:

- Product is shipped at room temperature.
- Lyophilized DNA should be stored at -20°C and is stable 3 months.
- Resuspended DNA should be stored at -20°C and is stable up to 1 year.
- Store *E. coli* Fast-Media® Zeo at room temperature. Fast-Media® pouches are stable 18 months when stored properly.

### Quality control:

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography.

### Materials required for antibody generation & isotype switching

- pFUSE2-CL Ig plasmid that features the constant region of the kappa or lambda light chains. pFUSE2-CL Ig plasmids are selectable with blasticidin (sold separately, see RELATED PRODUCTS).
- pFUSE-CHIg plasmid for the constant region of the heavy chain, this plasmid is selectable with Zeocin™.

## GENERAL PRODUCT USE

pFUSE-CHIg and pFUSE2-CL Ig plasmids are designed to change a monoclonal antibody from one isotype to another, therefore, enabling the generation of antibodies with the same antigen affinity but with different effector functions (increased or reduced ADCC and CDC). Furthermore, they can be used to produce entire IgG antibodies from Fab or scFv fragments that are either chimeric, humanized or fully human depending on the nature of the variable region.

pFUSE-CHIg and pFUSE2-CL Ig express the constant regions of the heavy (CH) and light (CL) chains, respectively. They contain a multiple cloning site (MCS) upstream of these constant regions to enable the cloning of the variable (VH and VL) regions of a given antibody. Transfection of mammalian cell lines with the recombinant pFUSE-CHIg and pFUSE2-CL Ig pair allows to generate an IgG antibody that can be purified from the supernatant using the appropriate Protein A, Protein G or Protein L affinity chromatography.

## Features of pFUSE-CHIg and pFUSE2-CL Ig plasmids

- **hEF1-HTLV prom**: is a composite promoter comprising the Elongation Factor-1α (EF-1α) core promoter<sup>1</sup> and the R segment and part of the U5 sequence (R-U5') of the Human T-Cell Leukemia Virus (HTLV) Type 1 Long Terminal Repeat<sup>2</sup>. The EF-1α promoter exhibits a strong activity and yields long lasting expression of a transgene *in vivo*. The R-U5' has been coupled to the EF-1α core promoter to enhance stability of RNA.
- **MCS**: The multiple cloning site contains several restriction sites that are compatible with many other enzymes, thus facilitating cloning.
- **SV40 pAn**: the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA<sup>3</sup>.
- **ori**: a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.
- **CMV enh / hFerL prom**: This composite promoter combines the human cytomegalovirus immediate-early gene 1 enhancer and the core promoter of the human ferritin light chain gene. This ubiquitous promoter drives the expression of the Zeocin™-resistance gene in mammalian cells.
- **EM2KC** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*. EM2KC is located within an intron and is spliced out in mammalian cells.
- **βGlo pAn**: The human beta-globin 3'UTR and polyadenylation sequence allows efficient arrest of the transgene transcription<sup>4</sup>.

## pFUSE-CHIg-hG4 specific features

- **Human IgHG4 (IgG4 heavy chain constant region)**: When cloning your heavy chain variable region of choice in the MCS, care must be taken to insert the gene in-frame and to preserve the integrity of the heavy chain constant region.
- **Zeo**: Resistance to Zeocin™ is conferred by the *Sh ble* gene from *Streptallotheichus hindustanus*. The same resistance gene confers selection in both mammalian cells and *E. coli*.

## References:

1. Kim DW. *et al.* 1990. Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. 91(2):217-23.
2. Takebe Y. *et al.* 1988. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol Cell Biol. 8(1):466-72.
3. Carswell S. & Alwine JC. 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. Mol Cell Biol. 9(10):4248-58.
4. Yu J. & Russell JE. 2001. Structural and functional analysis of an mRNP complex that mediates the high stability of human beta-globin mRNA. Mol Cell Biol. 21(17):5879-88.

## TECHNICAL SUPPORT

Toll free (US): 888-457-5873  
Outside US: (+1) 858-457-5873  
Europe: +33 562-71-69-39  
E-mail: info@invivogen.com  
Website: www.invivogen.com

## PROTOCOL

### Obtaining VH and VL sequences

To obtain the cDNA sequence of the VH and VL regions from an antibody producing hybridoma, total RNA or mRNA is extracted and reverse transcribed to cDNA. PCR is performed with 5' degenerate primers to anneal to the unknown VH and VL regions and the 3' primers designed to anneal to the “known” CH and CL regions. Alternatively 5' RACE can be used. The resulting amplicons must be sequenced.

### Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1  $\mu$ g/ $\mu$ l, resuspend the DNA in 20  $\mu$ l of sterile H<sub>2</sub>O. Store resuspended plasmid at -20°C.

### Cloning into pFUSE-CHIg and pFUSE2-CL Ig

Once the VH and VL sequence are known, inserts for cloning into the plasmids can be generated. In pFUSE-CHIg-hG4, the constant region of the human IgG4 heavy chain is preceded by a multiple cloning site containing four restriction sites: Eco RI, Eco RV, Xho I and Nhe I. The first three restriction sites can be used for insertion of the 5' end of the variable region including the native signal sequence. If the immunoglobulin signal sequence is unknown, pFUSEss plasmids containing a signal sequence should be used. In pFUSE-CHIg-hG4, Nhe I must be used for insertion of the 3' end of the variable region. Nhe I must be reconstituted to maintain the integrity of the constant region. Therefore we recommend to introduce by PCR an Nhe I site at the 3' end of the variable region in frame with the constant region.

#### Note:

- The 5' end of the variable region should encompass the native ATG initiation codon and the region immediately after which corresponds to the signal sequence. For proper initiation of translation, make sure that your insert contains a Kozak translation initiation sequence upstream of the ATG initiation codon such as (G/A)NNATGG.
- When generating the insert for VL, a Bsi WI (pFUSE2-CL Ig-hk; human kappa), or AvrII (pFUSE2-CL Ig-hl2; human lambda 2) site must be introduced at the 3' end. There is a choice of restriction sites at the 5' end.

### Antibody production

Cotransfect mammalian cells, such as 293 and CHO cells, with the recombinant plasmids pFUSE2-CL Ig encoding the light chain and pFUSE-CHIg encoding the heavy chain. Antibody production depends greatly on the ratio of heavy chain and light chain expression. Typically, pFUSE-CHIg to pFUSE2-CL Ig ratio of 2:3 is used to cotransfect mammalian cells. Since both plasmids share the same plasmid backbone, the appropriate heavy chain to light chain ratio can be easily determined by varying the quantities of plasmids.

OR


Transfect cells using a transfection agent, such as LyoVec™, with the plasmid coding for light chain and select the best clone. Following selection of the best clone, the plasmid coding for the heavy chain clone can be transfected into this clone.

Use blasticidin and Zeocin™ to select pFUSE2-CL Ig and pFUSE-CHIg respectively.


Antibody production can be analyzed by different techniques including SDS-PAGE, flow cytometry, ELISA, or a bioactivity assay.

## Antibody generation using pFUSE-CHIg & pFUSE2-CL Ig

### I- Obtention of VH and VL sequences



### 2- Cloning into pFUSE-CHIg and pFUSE2-CL Ig



### Antibody purification


The resulting IgG antibody can be purified from the supernatant using the appropriate Protein A, Protein G or Protein L affinity chromatography.

## RELATED PRODUCTS

Product	Catalog Code
pFUSE2-CL Ig-hk	pfuse2-helk
pFUSE2-CL Ig-hl2	pfuse2-hell2
pFUSE-CHIg-hG1	pfuse-hchgl
pFUSE-CHIg-hG2	pfuse-hchgl2
pFUSE-CHIg-hG3	pfuse-hchgl3
LyoVec™	lyec-12
Protein L / Agarose	gel-protl-2
Protein G / Agarose	gel-agg-5
Zeocin™	ant-zn-1
Fast-Media® Zeo TB	fas-zn-l
Fast-Media® Zeo Agar	fas-zn-s

## TECHNICAL SUPPORT

Toll free (US): 888-457-5873  
Outside US: (+1) 858-457-5873  
Europe: +33 562-71-69-39  
E-mail: info@invivogen.com  
Website: www.invivogen.com



**SgfI (11)**  
 1 GGATCTCGATCGTCCGGTCCCCGTCAAGTGGGAGAGCGCACATGCCACAGTCCCAGAAGTTGGGGAGGGTCGGCAATTGAACGGTGCCTA  
 101 GAGAACGGTGGCGGGGTAAACTGGAAAGTGATTCGTACTGGCTCGCTTTCCGAGGGTGGGGAGAACGTATAAGTCAGTAGTCGC  
 HindIII (246)  
**PvuII (242)**  
 201 GTGAACTTCTTTCGAACGGTTGCCAGAACACAGCTGAAGCTCGAGGGCTCGCATCTCCTCACCGCCCCGCCACCGTGGCC  
 301 GCCATCCACGCCGGTGGAGTCGCGTCTGCCCTCCGCTGTGGTGCCTCTGAACCTCGTCCCGCTAGGTAAAGCTCAGTCGAGACC  
 401 GGGCTTGTCCGGCTCCCTGGAGCCTACCTAGACTCAGCGGCTCTCACGCTTGCTGACCCCTGCTCAACTCTACGCTTTGTT  
 EcoRI (559)  
 AgeI (553) XhoI (570)  
 SgrAI (553) EcoRV (567) NheI (577)  
 501 TCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCCACCTGAGATCACGGTGAATTGATCTCGAGTCAACAGGGCCATCGTC  
 1▶ A S T K G P S V  
 AgeI (681)  
 601 TTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCGAGAGCACAGCCGCTGGCTGCTGGTAAGGACTACTCCCGAACCGTGACGGTGTGG  
 9▶ F P L A P C S R S T S E S T A L G C L V K D Y F P E P V T V S W  
 701 ACTCAGGCGCCCTGACCGCGCGTGCACACCTCCGGCTGTCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTACCGTGCCTCCAG  
 42▶ N S G A L T S G V H T F P A V L Q S S G L Y S L S S V V T V P S S  
 801 CTTGGGACGAAGACCTACACCTGCAACGTAGATCACAAGCCAGCAACCCAAGGTGAGCAAGAGAGTTGAGTCAAATATGGTCCCCATGCCATCA  
 75▶ L G T K T Y T C N V D H K P S N T K V D K R V E S K Y G P P C P S  
 BspHI (968) BbrPI (995)  
 901 TGCCCCAGCACCTGAGTTCTGGGGGACCATCAGTCTCTGTTCCCCAAAACCCAAGGACACTCTCATGATCCCGGACCCCTGAGGTACAGTCG  
 109▶ C P A P E F L G G P S V F L F P P K P K D T L M I S R T P E V T C  
 1001 TGGGGTGGACGTGAGCCAGGAAGACCCCGAGGTCAGTTCAACTGGTACGTGGATGGCTGGAGGTGCATAATGCCAAGACAAGCCGGAGGAGCA  
 142▶ V V V D V S Q E D P E V Q F N W Y V D G V E V H N A K T K P R E E Q  
 StuI (1196) Eco147I (1196)  
 1101 GTTCAACAGCACGTACCGTGTGGTCACTGGCTCTCACCGCTCTGACCCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCAACAAAGGCC  
 175▶ F N S T Y R V V S V L T V L H Q D W L N G K E Y K C K V S N K G L  
 BsrGI (1259)  
 1201 CCGCTCTCCATCGAGAAAACATCTCAAAGCCAAGGGCAGCCCCGAGGCCACAGGTGACACCTCTCCAGGAGATGACCAAGAAC  
 209▶ P S S I E K T I S K A K G Q P R E P Q V Y T L P P S Q E E M T K N  
 1301 AGGTCAAGCTGACTCGCTGGTCAAAGGCTCTACCCAGCGACATGCCGTGAGTGGAGAGCAATGGCAGCCGAGAACAACCTACAAGACCACCC  
 242▶ Q V S L T C L V K G F Y P S D I A V E W E S N G Q P E N N Y K T T P  
 XmnI (1480)  
 1401 TCCCGTGTGGACTCCGACGGCTCTCTTCTACAGCAGGCTCACCGTGGACAAGAGCAGGGAGGAAATGTCTCTCATGCTCGTGATG  
 275▶ P V L D S D G S F F L Y S R L T V D K S R W Q E G N V F S C S V M  
 MscI (1571)  
 1501 CATGAGGCTCTGACAACCAACTACACAGAAGAGCCTCTCCCTGCTCCGGTAATGAGTCCTAGCTGGCAGACATGATAAGATACATTGAGTT  
 309▶ H E A L H N H Y T Q K S L S L S P G K •  
 1601 TGGACAAACCAACTAGAATGCACTGAAAAAAATGTTATTGATGCTATTGTTAACCATTATAAGCTGCAATAAACAA  
 HpaI (1703) AseI (1800)  
 1701 GTTAAACAACAATTGATTCTATTTATGTTCAAGGTCAGGGGAGGTGTGGAGGTTAAAGCAAGTAAACCTCTACAAATGTGGTATGAAAT  
 1801 TAATTCTAAAATACAGCATAGCAAAACTTAACCTCAAATCAAGCTACTTGAATCTCTGAGGGATGATAAGGCATAGGCATAGGGCTGT  
 1901 TGCCAATGTGCATTAGCTGTTGAGCCTCACCTCTTATGGAGTTAAGATATAGTGTATTCCCAAGGTTGAACTAGCTCTCATTTATG  
 SwaI (2057)  
 2001 TTTAAATGCACTGACCTCCACATCCCTTTAGTAAATATTCAAATTTAATCATTGCAATGAAATAATGTTTATTAGGCAG  
 2101 ATTCAGATGCTCAAGGCCCTCATATAATCCCCAGTTAGTGTGGACTTAGGAAACAAGGAACCTTAATAGAAATTGGACAGCAAGAACGAG  
 2201 CTTCTAGCTTACCTCAGTCTCTCTGCCACAAAGTCACCGAGTTGGCCGGGGTCCGGCAGGGGAACCTCCGGCCACGGCTGCTCCGA  
 125▶ • D Q E E A V F H V C N G A P D R L A F E R G W P Q E G I  
 2301 TCTCGGTATGGCCGGCCGGAGGCGTCCCGGAAGTCTGTGGACACGACCTCCGACCACTCGCGTACAGTCGTCAGGCCGCACCCACACCCAGG  
 96▶ E T M A P G S A D R F N T S V V E S W E A Y L E D L G R V W V W A  
 SgrAI (2470) XmaI (2496)  
 2401 CAGGGTGTGCGCACCCCTGGCTCTGGACCGCGCTATGAACAGGGTACGTCGCCCCGACACCGGCAAGTCGTCCTCCACGAAGTCGG  
 63▶ L T N D P V V Q D Q V A S I F L T V D D R V V G A F D D E V F D R  
 Mscl (2585)  
 2501 GAGAACCCGAGCGGGTGGTCCAGAACATCGACCGCTCCGGCAGCTCGCGCGGGTGGACCCGGAACGGCACTGGTCAACTGGCATGATGGCTCTC  
 29▶ S F G L R D T W F E V A G A V D R A T L V P V A S T L K A M  
 AseI (2684)  
 2601 ctgtcaggagaggaaagagaagaaggtagtacaattgCTATAGTGAATTACTATGCAAGATATACTATGCCAATGATTAATTGTCAAACTAGG

**PstI (2706)**  
 2701 **GCTGCAgggttcatagtgcactttcctgactgccccatctcccccaccccccaggcatagacagtca**gtcactgacttacCAAACTCACAGGAGGG  
**HindII (2810)**  
 2801 **AGAAGGCAGAAGCTTGAGACAGACCCGGGGACCGCGAACACTCGCAGGGACGTGGCTAGGGCGCTTATGGTGC**CCGGCCCTCGGAGGCAGGG

---

**StuI (2912)**  
**Eco147I (2912)**  
 2901 **CGCTCGGGAGGCCATTAGCGGCCAATCTCGGTGGCAGGGGGCCGAAGGCCGTGCCTGACCAATCCGGAGCACATAGGAGTCAGCCCCCCC**

---

**BspEI (2968)**  
 3001 **CAAAGCAAGGGGAAGTCACGCGCCTGTAGGCCAGCGTGTGTGAAATGGGGCTTGGGGGCTGACTAGTC**AAAACAACTCCATTGAC

---

**SpeI (3075)**  
 3101 **GTCAATGGGGTGGAGACTTGGAAATCCCCGTGAGTCAAACCGCTATCCACGCCATTGATGTA**CTGCCAAACCGCATCATGGTAATAGCGATGACT

---

**SnaBI (3205)**  
 3201 **AATACGTAGATGTACTGCCAAGTAGGAAAGTCCCATAAGGTCATGTA**CTGGCATAATGCCAGGGCCATTACCGTATTGACGTCAATAGGGGCG

---

**NdeI (3309)**  
 3301 **TACTTGGCATATGATA**CACTTGTACTGCCAAGTGGCAGTTACCGTAAATACTCCACCCATTGACGTCAATGAAAGTCCTATTGGCCTACTAT

---

**PacI (3498)**  
**PstI (3491)**  
**SdaI (3491)**

3401 **GGGAACATACGT**CATTATTGACGTCAATGGCGGGGTCGTTGGCGGTAGCCAGGCGGGCATTACCGTAAGTTATGTAACGCCAGGTTAATTA

---

**BspLU11I (3504)**  
 3501 **AGAACATGTGAGCAAAGGCCAGCAAAGGCCAGGAACCGTAA**AAAGGCCGTTGCTGGCGTTTCATAGGCTCCGCCCCCTGACGAGCATCAAA

---

3601 **AAATCGACGCTCAAGTCAGAGGTGGCAAACCGACAGGACTATAAAGATA**CCAGGCCTTCCCTGGAAAGCGTGGCCTTCTCATAGCTCACGCTGTAGGTATCTCAGTCGGTGTAGGTGTC

---

3701 **CTGGCGCTTACCGGATACTGTCCGCC**TTCTCCCTGGAAAGCGTGGCCTTCTCATAGCTCACGCTGTAGGTATCTCAGTCGGTGTAGGTGTC

---

3801 **GCTCCAAGCTGGCTGTGTCACGAACCCCCGTT**CAGCCGACCGCTGCCATTCCGGTAACTATGCTCTGAGTCCAACCCGTAAGACACGACTT

---

3901 **ATGCCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTA**GGCGGTGCTACAGAGTTCTGAAGTGGTGGCTAACTACGGCTACACT

---

4001 **AGAAGAACAGTATTGGTATCTCGCCTCTGCTGAAGCCAGTTACCTCGA**AAAAGAGTTGGTAGCTCTGATCCGCAAACAAACCCACCGCTGGTAGCG

---

4101 **GTGGTTTTTGTGTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATC**TTGATCTTCTACGGGTCTGACGCTCAGTGGAACGA

---

**PacI (4238) SwaI (4246) NotI (4254)**

4201 **AAACTCAGTTAAGGGATTTGGT**CATGGCTAGTTAATTAACATTAAATCAGCGGCCGAATAAAATATCTTATTTATTACATCTGTGTGGTT

---

4301 **TTTGTGTGAATCTGTA**ACTAACATACGCTCCATCAAAACAAACGAAACAAACAAACTAGCAAATAGGCTGCCCCAGTGCAGTGAGGTGCCAG

4401 **ACACATTCTCTATCGAA**